AstraZeneca to Invest in Indian TB Facility
June 2, 2003
The Anglo-Swedish pharmaceuticals group AstraZeneca is to announce today that it is investing $30 million to develop TB treatments at a new research facility in India. Any drugs developed at the facility -- which would be the first new TB treatments in 40 years -- would be sold in the developing world at "low prices," the company said. The TB research program will be based at the company's new research center in Bangalore, which will employ 100 scientists. Although India has a strong base of research scientists, few multinational drug companies have invested in research there because of the weaker patent protection they receive for drugs. Stung by criticism that they have long neglected diseases common in the developing world, a number of pharmaceutical companies have recently outlined research investments in this area.Adapted from:
Financial Times (United Kingdom)
This article was provided by CDC National Prevention Information Network. It is a part of the publication CDC HIV/Hepatitis/STD/TB Prevention News Update.